Phase 2 N=35 Pazopanib in Treating Patients With Recurrent Glioblastoma
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: 6 Months Progression-free Survival — 3 percent
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=62 Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Primary: ORR — 0; 0; 0; 0 percentage of patients
Phase 2 N=58 Dose-Intense Temozolomide in Recurrent Glioblastoma
Glioblastoma · Gliosarcoma
Primary: 6 Month Progression Free Survival — 11 percentage of evaluable participants
Phase 1 N=20 Ketogenic Diet for Recurrent Glioblastoma
Recurrent Glioblastoma
Primary: Applicability as Measured by Discontinuation of Study Treatment Due to Intolerability — 15 percent of participants
N/A N=20 Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma
Adult Glioblastoma
Primary: Number of Participants Who Received Treatment Recommendations Within 35 Days of Surgery — 15 Participants
Phase 2 N=158 A Study in Recurrent Glioblastoma (GB)
Glioblastoma
Primary: Overall Survival (OS) — 8.0; 6.7; 7.5 Months
Phase 2 N=123 Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
Adult Glioblastoma · Adult Gliosarcoma · Recurrent Adult Brain Neoplasm
Primary: Count/Percentage of Patients Progression-free at 6 Months for Bevacizumab and Irinotecan Hydrochloride Arm — 22 Participants
Phase 3 N=35 Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Recurrent or Progressive Glioblastoma
Primary: Local Tumor Control — 14; 4 Participants
Phase 2 N=88 Bevacizumab for Recurrent Malignant Glioma
Recurrent High-Grade Gliomas · Malignant Gliomas
Primary: Percentage of Participants With Progression Free Survival at 6 Months. — 20.9; 29 Percentage of participants
Phase 2 N=37 BIBF 1120 for Recurrent High-Grade Gliomas
Glioblastoma · Gliosarcoma · Anaplastic Astrocytoma
Primary: 6-Month Progression Free Survival — 0 percentage of participants
Phase 2 N=80 Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
Adult Glioblastoma Multiforme
Primary: Percentage of Participants Who Achieved Progression-Free Survival Rate at 6 Months (PFS-6) — 12.5; 7.5 percentage of participants
Phase 2 N=31 Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM
Glioblastoma Multiforme · Brain Tumor
Primary: Progression-free Survival (PFS) — 91.3 percentage of participants
Phase 2 N=44 GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: 6 Months Progression-free Survival (PFS) — 0; 5 percentage of patients
Phase 2 N=81 Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
Glioblastoma Multiforme
Primary: Percentage of Subjects With Progression-free Survival — 7.5; 15.0 percentage of subjects
Phase 2 N=54 Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Brain and Central Nervous System Tumors
Primary: 6-month Progression-free Survival — 0.263; 0.171 proportion of participants
Phase 2 N=66 BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
IDH1 Mutation · IDH2 Mutation · Recurrent Glioblastoma
Primary: Participants With Dose Limiting Toxicity (DLT) Rate Less Than or Equal to 33% (Dose Level 1) — 0; 7 Participants
Phase 2 N=151 A Study in Subjects With Recurrent Malignant Glioma
Glioma
Primary: Progression Free Survival (PFS) Rate at Month 6 — 11.0; 21.2; 8.0; 7.6 Percentage of participants
Phase 2 N=60 Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Glioblastoma
Primary: Objective Response Rate (ORR) — 1; 3 Participants
Phase 2 N=115 Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Adult Glioblastoma · Adult Gliosarcoma · Recurrent Adult Brain Neoplasm
Primary: Progression-free Survival — 17.1; 9.7 Proportion of Successes
Phase 2 N=60 Temozolomide in Treating Patients With Recurrent High-Grade Glioma
Recurrent Central Nervous System Neoplasm
Primary: 6 Month Progression-free Survival — 10; 50 percentage of patients
Phase 2 N=182 Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Overall Survival — 25.1; 21.6 percentage of participants — p=0.46
Phase 2 N=68 Bevacizumab Beyond Progression (BBP)
Malignant Glioma · Grade 4 Malignant Glioma · Glioblastoma
Primary: Overall Survival — 17.8 months
Phase 2 N=41 Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Recurrent Glioblastoma
Primary: Progression Free Survival (PFS) — 34.5 percentage of participants
Phase 2 N=80 Pembrolizumab +/- Bevacizumab for Recurrent GBM
Glioblastoma
Primary: Pembrolizumab Maximum Tolerated Dose (MTD) [Cohort A Safety Lead-In] — 200 mg every 3 weeks
Phase 2 N=59 Ph II Bevacizumab + Etoposide for Pts w Recurrent MG
Glioblastoma · Gliosarcoma
Primary: 6 Month Progression-Free Survival (PFS) — 41; 44 percentage of participants
Phase 2 N=56 A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
Glioblastoma Multiforme
Primary: Progression-free Survival Rate at 6 Months — 15.4 Percentage of participants
Phase 2 N=85 Amgen 386 for Recurrent Glioblastoma
Glioblastoma Multiforme
Primary: 6-Month Progression-Free Survival (PFS6) [Cohort A and Cohort B] — 0.243; 0 proportion of participants
Phase 2 N=32 A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme
Glioblastoma Multiforme
Primary: Progression-Free Survival (PFS) - Percentage of Participants With an Event — 96.88 percentage of participants
Phase 2 N=58 Everolimus in Treating Patients With Recurrent Low-Grade Glioma
Adult Diffuse Astrocytoma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: Progression-free Survival at 6 Months. — 39; 6 Participants
Phase 2 N=40 Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
Glioblastoma · Recurrent Glioblastoma · Brain Tumor
Primary: Efficacy: Median Progression-free Survival (PFS) Rate at 6 Months (PFS-6) — 22.5; 25.0; 18.2 Percentage (%) of subjects